Gary has extensive leadership experience in discovery to late clinical-stage cell and gene therapy and regenerative medicine. He brings deep expertise in product development, operations and translational research, with more than 26 years’ experience in AAV and lentiviral vector biology, manufacturing, and testing. Gary has additional experience in building programs and platforms, due diligence, team management and oversight of contract research organizations, as well as expert-level knowledge of confidentiality agreements, material transfer agreements and work scopes with CROs and collaborators. Gary has published 10 patents and 28 scientific papers, and his scientific opinion on patent submissions is frequently engaged by legal counsel.
Areas of Expertise
- Translational Consulting: Expert in analyzing existing capabilities, identifying skill gaps, streamlining work scopes, and implementing preclinical strategies to transition companies quickly to early clinical trials.
- Development: Building and developing R&D teams, leading to pre-IND and IND submissions and orphan drug designations.
- Partnership Oversight: Managed dozens of critical relationships with academia, corporate partners and CROs, adding value in the form of qualified processes, patents, publications and federal grants.
- Technology Assessment: Evaluating and developing platform technologies and performing due diligence activities, leading to IP generation and asset acquisition.
